Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.

In this study, kolaviron and quercetin were found to reverse elevated biomarkers associated with testosterone-induced benign prostatic hyperplasia in Wistar rats, with both treatments effectively increasing HDL-c levels, though quercetin did not significantly affect triglyceride levels.

In this study, researchers found that androgen receptor gene polymorphism is associated with higher androgenetic alopecia grades and PSA levels in men with benign prostatic hyperplasia, but not with prostate cancer.

This review discusses the role of DHT in male sexual differentiation and fertility in individuals with 5α-reductase-2 deficiency, reporting no new clinical results.

This review discusses the pathophysiology of androgen-stimulated skin disorders and key clinical trials of 5α-reductase inhibitors for their treatment, but it does not report new clinical results.

Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.

This study concluded that cyproterone acetate alone produced antiandrogenic effects on the female gerbil prostate, while ethinyloestradiol alone stimulated estrogenic activity, and their combination led to prostatic lesions.

This study used machine learning to develop classifiers for identifying effective inhibitors of 5α-reductase isozyme 2, achieving high performance in distinguishing potent from weak inhibitors.

This review discusses the pharmacological properties and clinical applications of cyproterone acetate and similar antiandrogens, noting previous failures in local applications due to concentration limitations; it reports no new empirical results.

This study identified 63 genetic loci associated with male-pattern baldness, uncovering genes and pathways that may help develop treatments and suggesting its connection to other human conditions.

This review found that androgenetic alopecia may be associated with increased risks of cardiovascular disease, metabolic disorders, and mental health impacts, suggesting its potential as a biomarker for systemic conditions.

This review summarizes the latest evidence on testosterone, detailing its clinical indications, diagnostic tests, and impacts on various male organs, while also noting its association with aging, metabolic disorders, and increased mortality risk due to androgen deficiency.

Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.

This workshop review from the Australian Hair and Wool Research Society discusses findings in cutaneous biology and endocrinology but presents no new research results.

The book explains causes and treatments for common hair loss, its psychological effects, related health risks, and emphasizes early screening and lifestyle changes.

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.

This review summarizes recent research and patents on 17β-HSD3, 17β-HSD5, and 3α-HSD3 inhibitors, suggesting their potential in treating androgen-dependent diseases, but reports no new clinical results.

This review discusses the natural progression of androgenetic alopecia and potential factors influencing its long-term prognosis, reporting no new clinical results.

This review discusses the biochemical properties and clinical significance of 5 alpha-reductase isozymes and reports no new clinical results.

This review details the prevalence and management of ejaculatory disorders in men with benign prostatic hyperplasia-related urinary symptoms and highlights the importance of preserving peri-montanal tissue during treatment to maintain antegrade ejaculation.

This study reported that a novel cationic liposome formulation for delivering encapsulated Cas9 protein and sgRNA successfully decreased SRD5α2 mRNA expression by 29.7% in vitro, suggesting a potential alternative treatment option for conditions like prostate cancer and benign prostatic hyperplasia without current drug side effects.

This article reviews the use of cyproterone acetate for conditions like prostate cancer and sexual disorders, highlighting its effects on libido but reporting no new specific trial results.

Finasteride safely treats enlarged prostate and male-pattern baldness.

This review discusses the role of 5α-reductase enzymes in androgen action and related disorders, noting that their specific inhibitory drugs show promise for conditions like benign prostatic hypertrophy; it reports no new clinical results.

This study details the isolation and characterization of the human type II 5 alpha-reductase gene, which may play a role in male pseudohermaphroditism, prostate cancer, and benign prostatic hyperplasia.

This review discusses the association between androgen receptor CAG repeat polymorphism and several health conditions, including Kennedy’s disease and urologic disorders, without reporting new clinical results.

This study suggests that early onset androgenetic alopecia in men may indicate a male PCOS equivalent, possibly leading to higher risks of metabolic and cardiovascular disorders later in life.

This study found that GI198745 acts as a time-dependent inhibitor of rat 5α-reductase type 2 but a rapid-equilibrium inhibitor of type 1, potentially making it more effective than finasteride in preventing rat prostate growth.

This study found that Monascus cursory extraction reduced baldness, prostate hyperplasia, and tumor incidence in animal models of androgen-related diseases, suggesting it may be a promising new therapeutic candidate.

This study found that women with PCOS have higher total PSA levels than controls, and the total PSA level correlates positively with testosterone and free androgen index.